Podcasts about pieter sonneveld

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk multiple myeloma (MM)?In this podcast, Sonneveld discusses trial results presented during EHA2021 on the efficacy of novel treatments for patients with high-risk MM, a patient group associated with poor outcomes and shorter remission rates. He believes that identifying high-risk patients and selecting them for more intensive targeted maintenance treatment could be crucial in preventing relapse. Hosted on Acast. See acast.com/privacy for more information.

Prof. dr. Pieter Sonneveld, internist-hematoloog in het Erasmus MC Kanker Instituut te Rotterdam licht in deze podcast de EMN011/HOVON 114-studie toe. In deze studie worden nieuw-gediagnosticeerde multiple myeloompatiënten die progressie/relaps vertonen na de standaard eerstelijnsbehandeling behandeld met tweedegeneratieproteasoomremmers (carfilzomib) en tweedegeneratie-IMID’s (pomalidomide) in combinatie met dexamethason.Referentie1. Sonneveld P, et al. ASH 2018; abstr 801.

Interview with Pieter Sonneveld, from The Netherlands. Pieter Sonneveld discusses the topic 'Is multiple myeloma a curable disease'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Pieter Sonneveld, from The Netherlands. Pieter Sonneveld discusses the topic 'Is multiple myeloma a curable disease'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Join us as we talk Dr. Pieter Sonneveld, MD, PhD, who is the Chairman of the European Myeloma Network and Chairman of the HOVON Foundation about advances in myeloma in Europe and throughout the world. 

Dr Pieter Sonneveld, Prof Michele Cavo, Dr Jesus San Miguel and Dr Meletios Dimopoulos discuss the highlights from the Multiple Myeloma Debate in Copenhagen The panel discusses the most recent data presented on: Current and emerging treatment paradigms: Choice between sequential or combination therapy for MM The role of new therapies such as pomalidomide Role of carfilzomib plus melphalan and prednisone as the upfront therapy of elderly patients with MM New agents, such as MLN-9708, (an oral proteasome inhibitor), and daratumumab (an anti-CD38 monoclonal antibody) Relapsed MM: Defining the correct sequence of novel agents in the treatment of relapsed MM Recognising and responding to resistance in relapsed MM Primary refractory or multiply-relapsed MM: What are our options? Transplantation: The role of allotransplant in the era of novel therapies How salvage autologous stem cell transplantation (ASCT) can achieve sustained disease control in recurrent MM Optimal pre-transplant therapy Best practice for post transplantation consolidation and maintenance therapy This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Hoe speel je je als bedrijf in de kijker? Zeker wanneer de klanten niet meer vanzelf binnenstromen. Dirkzwager advocaten en notarissen koos voor het delen van hun kennis. Jeroen Zweers en Pieter Sonneveld vertellen in Top Names over het hoe en waarom.

Prof Pieter Sonneveld talks to ecancer at the 18th EHA Congress in Stockholm, Sweden about the issues with ageing in blood related cancers. Prof Sonneveld highlights several issues with aging in blood disorders and at a higher age people are more likely to get blood cancers. Patients with already with disorders are more likely to develope additional issues.